BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Carb-X - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Carb-X
X-ORIGINAL-URL:https://carb-x.org
X-WR-CALDESC:Events for Carb-X
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20181028T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20201025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Madrid
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200512T110000
DTEND;TZID=America/New_York:20200512T123000
DTSTAMP:20260403T232903
CREATED:20200330T142407Z
LAST-MODIFIED:20200422T140709Z
UID:3941-1589281200-1589286600@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Probability of target attainment analyses for dose selection in antimicrobial drug development
DESCRIPTION:Speaker: Shampa Das\, Senior Lecturer\, Centre of Excellence in Infectious Diseases Research\, University of Liverpool (UK)  \nModerator: Vincent H. Tam\, Professor\, University of Houston (US)  \nIn this webinar\, Shampa Das will give an overview of her work in studying the PK/PD and probability of target attainment for dose selection. \nTopics discussed will include: \n\nAn overview of what is meant by the probability of target attainment (PTA)\nHow it is calculated and what data is used for this\nHow PTA is used for decision making during drug development\n\nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 12 May 2020\, 17:00-18:30 CEST (find your time zone here).
URL:https://carb-x.org/event/live-webinar-gardp-revive-probability-of-target-attainment-analyses-for-dose-selection-in-antimicrobial-drug-development/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200428T110000
DTEND;TZID=America/New_York:20200428T123000
DTSTAMP:20260403T232903
CREATED:20200330T142019Z
LAST-MODIFIED:20200422T140647Z
UID:3937-1588071600-1588077000@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Inhaled antimicrobials: Do we get the drug to the bug?
DESCRIPTION:Speaker: Harm A. W. M. Tiddens\, Professor of Pediatric Pulmonology and Allergology\, Erasmus Medical Center Sophia Children’s Hospital (Netherlands) \nModerator: Harpal Singh Dhillon\, Global Medical Value Director & Founder\, AntiBx (UK)\n \nIn this webinar\, Harm Tiddens will discuss the relation between structural and functional abnormalities of the lung and how this can impact upon the deposition pattern and efficacy of inhaled antibiotics. He will further present the learnings of his research group’s computational fluid dynamic modelling studies and explain why the expectation that inhaled antibiotics result in high concentrations in the lung is unfortunately a misconception. \nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 28 April\, 17:00-18:30 CEST (find your time zone here).
URL:https://carb-x.org/event/live-webinar-gardp-revive-inhaled-antimicrobials-do-we-get-the-drug-to-the-bug/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200320T090000
DTEND;TZID=America/New_York:20200320T170000
DTSTAMP:20260403T232903
CREATED:20200214T151818Z
LAST-MODIFIED:20200214T151818Z
UID:3792-1584694800-1584723600@carb-x.org
SUMMARY:BAARN2020: Boston Area Antimicrobial Research Network Meeting
DESCRIPTION:The Boston Area Antimicrobial Resistance Network Meeting\, to be held on Friday\, March 20th. \n\nBAARN2020 will be the 7th iteration of this flagship MSI event\, bringing together our collective talents across academia and industry to address the persistent dilemma posed by antimicrobial resistant infection.\n \nTalks will begin at 9 AM in the Northwest Labs Building at 52 Oxford Street\, Cambridge MA 02138\, and our sessions will conclude with the annual Stuart Levy Lecture. A reception will follow at 6 PM at the Harvard Museum of Natural History next door.
URL:https://carb-x.org/event/baarn2020-boston-area-antimicrobial-research-network-meeting/
LOCATION:Harvard Campus\, 52 Oxford Street\, Cambridge\, MA\, 02138\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200227T110000
DTEND;TZID=America/New_York:20200227T123000
DTSTAMP:20260403T232903
CREATED:20200127T163753Z
LAST-MODIFIED:20200127T163906Z
UID:3761-1582801200-1582806600@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE - PK/PD murine infection models: Focus on study elements\, variability\, and interpretation of results
DESCRIPTION:In this webinar\, Alexander J. Lepak will review critical study elements that lead to robust preclinical PK/PD results in the murine model. \nTopics discussed will include: \n\nUnderstanding and embracing the inherent variability in many components of the murine model\nDemonstrating how to generate and interpret preclinical murine model PK/PD results\n\nThe presentation will be followed by a Q&A session. \nThe material presented in this webinar was shown but not recorded at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019. \nSpeaker: Alexander J. Lepak\, Assistant Professor\, Department of Medicine\, University of Wisconsin School of Medicine and Public Health (USA) \nModerator: Peter Warn\, Evotec (UK) \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-pk-pd-murine-infection-models-focus-on-study-elements-variability-and-interpretation-of-results/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200204T110000
DTEND;TZID=America/New_York:20200204T123000
DTSTAMP:20260403T232903
CREATED:20200127T162038Z
LAST-MODIFIED:20200127T162038Z
UID:3752-1580814000-1580819400@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE - Non-traditional antibacterial therapeutic options and challenges
DESCRIPTION:In this webinar\, the following aspects will be presented: \n\nDiscovery and early development of “non-traditional” antibacterial approaches is a noticeable trend in the pre-clinical global pipeline\nThese approaches include anti-virulence strategies\, microbiome-modifying therapies\, phages and others such as nanoparticles\, immunotherapy and drug-resistance modulation\nSome of these approaches require novel preclinical efficacy models to predict clinical outcome\nPathogen-specific or even patient-specific strategies dominate this field\nA major challenge will be to show efficacy in clinical trials\n\nThe presentation will be followed by a Q&A session with Ursula Theuretzbacher and Laura Piddock (GARDP). \nSpeaker: Ursula Theuretzbacher\, CEFAIA\, Austria \nModerator: Prabhavathi Fernandes\, Chair of GARDP’s Scientific Advisory Committee \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-non-traditional-antibacterial-therapeutic-options-and-challenges/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200121T110000
DTEND;TZID=America/New_York:20200121T123000
DTSTAMP:20260403T232903
CREATED:20200127T162345Z
LAST-MODIFIED:20200127T162345Z
UID:3755-1579604400-1579609800@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE - Testing for the potential of emergence of antimicrobial resistance
DESCRIPTION:In this webinar\, the following aspects will be presented: \n\nWhat are the most common techniques used to measure the extent of the risk of selecting for resistance when using a novel direct-acting antibacterial. What are the advantages and limitations of these techniques?\nWhat are some techniques that may be used to understand the origins of resistance selection?\nHow to rationalize/manage the risk of translation of the resistance selection from in vitro to the clinical settings?\n\nThe presentation will be followed by a Q&A session. \nThis presentation was also part of the ‘Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process’\, jointly organized by GARDP\, CARB-X\, REPAIR Impact Fund\, JPIMAR and Wellcome Trust at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019.  \n  \nSpeaker: Michael Mourez\, Head BacteriOmics Platform\, Evotec (France) \nModerator: Laura Piddock\, Director Scientific Affairs\, GARDP \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-testing-for-the-potential-of-emergence-of-antimicrobial-resistance/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200121T080000
DTEND;TZID=America/New_York:20200121T170000
DTSTAMP:20260403T232903
CREATED:20200127T163257Z
LAST-MODIFIED:20200127T163257Z
UID:3757-1579593600-1579626000@carb-x.org
SUMMARY:Davos 2020 World Economic Forum - Novo Nordisk Foundation and Novo Holdings: The Broken Model of Antimicrobial resistance
DESCRIPTION:Moderator: Kevin Outterson\, Executive Director\, CARB-X\, Professor of Law\, Boston University \nPanel: \n\nLars Rebien Sorensen\, Chairman of the Novo Nordisk Foundation and Novo Holdings\nJeremy Farrar\, Director\, Wellcome Trust\nDr. Malin Grape\, Head of Antibiotics Unit\, The Public Health Agency of Sweden\nThomas Cueni\, Director General\, IFPMA\nJayasree K. Iyer\, Executive Director\, Access to Medicine Foundation\nFrancesca Colombo\, Head of the Health Division\, OECD\n\nAntimicrobial resistance is one of the biggest threats to human health. The Novo Nordisk Foundation is hosting a session at the World Economic Forum’s Annual Meeting in Davos urging governments\, the biopharma industry and other stakeholders to step up the urgency and respond to the crisis in #antimicrobialresistance with new funding models.  \nTo watch a recording of this panel\, please click here. 
URL:https://carb-x.org/event/davos-2020-world-economic-forum-novo-nordisk-foundation-and-novo-holdings-the-broken-model-of-antimicrobial-resistance/
LOCATION:DAVOS-KLOSTERS\, Switzerland
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200116T103000
DTEND;TZID=America/New_York:20200116T163000
DTSTAMP:20260403T232903
CREATED:20191206T175155Z
LAST-MODIFIED:20191206T175155Z
UID:3653-1579170600-1579192200@carb-x.org
SUMMARY:Exploring Opportunities to Reform Antimicrobial Payment and Post-Market Incentives
DESCRIPTION:Speakers include Kevin Outterson\, Executive Director of CARB-X. \nThe rise of antimicrobial resistance and the corresponding lack of novel antibiotic development impacts the ability of physicians to provide appropriate care for patients. The greatest barriers to a robust antibiotic ecosystem are low return on investment (ROI) and limited market opportunities\, in part due to payment decisions that don’t reflect the value of antibiotics that extends beyond the hospital stay. For years\, policy makers and other stakeholders have been exploring ways to improve the antibiotic ecosystem through development\, regulatory\, and market incentives proposals\, though to date there has been limited impact on manufacturers’ ability to generate adequate ROI. \nThis public meeting will highlight recent actions implemented by stakeholders in the U.S. and globally\, and present additional opportunities to effect change to payment and the costs and returns to antimicrobial investment systems through legislative\, administrative\, and private sector mechanisms.
URL:https://carb-x.org/event/exploring-opportunities-to-reform-antimicrobial-payment-and-post-market-incentives/
LOCATION:Washington Marriott at Metro Center\, 775 12th Street NW\, Washington\, DC\, 20005\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191126T033000
DTEND;TZID=America/New_York:20191126T050000
DTSTAMP:20260403T232903
CREATED:20191031T131530Z
LAST-MODIFIED:20191113T153543Z
UID:3583-1574739000-1574744400@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Innovation in point-of-care diagnostics for sepsis and bloodstream infections
DESCRIPTION:In this webinar our moderator Caroline Purslow (Nesta Challenges) will welcome three speakers. \nTill Bachmann (University of Edinburgh) will give an overview of recent advances in AMR diagnostics development. He will discuss: \n\nState of the art approaches for diagnosing infections and AMR\nPipeline of promising tests\nChallenges of adoption\n\nAmrita Sukrity (SpotSense) will draw from her experience as a founder of SpotSense and talk about diagnosis of neonatal sepsis at the community level. Topics discussed will include: \n\nChallenges across diagnosing newborn sepsis in NICU vs. in the community\nIdentifying different phases of sepsis by combining risk parameters and biomarker data\nCreating outlines for biomarker-based differential diagnosis: work ahead\n\nAnd finally\, David Anderson’s (Burnet Institute) presentation ‘CD64 as a host-response biomarker in sepsis and severe infections’ will cover: \n\nLimitations of flow cytometry for CD64 as a diagnostic tool of sepsis and severe infections in emergency situations\nNovel observations on CD64 biology that should facilitate more sensitive a point-of-care (POC) diagnostic tests for sepsis and severe infections\nThe ongoing development of a POC diagnostic test for neutrophil CD64\n\nThe presentations will be followed by a Q&A session. \nRegister here for this live webinar. \nA recording of this webinar will be available on revive.gardp.org/webinars.
URL:https://carb-x.org/event/live-webinar-gardp-revive-innovation-in-point-of-care-diagnostics-for-sepsis-and-bloodstream-infections/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191118
DTEND;VALUE=DATE:20191120
DTSTAMP:20260403T232903
CREATED:20191010T184500Z
LAST-MODIFIED:20191010T184546Z
UID:3517-1574035200-1574207999@carb-x.org
SUMMARY:FDA Workshop: Enhancing the Clinical Trial Enterprise for Antibacterial Drug Development in the United States
DESCRIPTION:Presenters include Kevin Outterson\, Executive Director of CARB-X\, and Erin Duffy\, CARB-X Chief of Research and Development. \nThe FDA\, IDSA\, NIAID and Pew are co-sponsoring this workshop to focus on Enhancing the Clinical Trial Enterprise for Antibacterial Drug Development in the United States. This workshop will bring together a diverse array of subject matter experts in the fields of infectious diseases (ID)\, academics and industry and other government bodies to better understand the current state of U.S. based ID trials and how to enhance enrollment and research in such trials. \nTo learn more\, click here.  \nRegistration:\nThose who are interested in attending this public workshop either in-person or by web viewing must register here by 11:59 pm on November 14\, 2019. Onsite registration will begin at 7:30 am the day of the meeting. Please plan to arrive 30 minutes prior for security processing.
URL:https://carb-x.org/event/fda-workshop-enhancing-the-clinical-trial-enterprise-for-antibacterial-drug-development-in-the-united-states/
LOCATION:FDA White Oak Campus – Building 31\, 10903 New Hampshire Ave\, Silver Spring\, MD\, 20993\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191114
DTEND;VALUE=DATE:20191116
DTSTAMP:20260403T232903
CREATED:20190913T155211Z
LAST-MODIFIED:20191114T171317Z
UID:3425-1573689600-1573862399@carb-x.org
SUMMARY:The 2019 Canada Gairdner Foundation / Ontario International Symposium: Fuelling the Fight against AMR - Global Innovations in Research & Discovery
DESCRIPTION:Kevin Outterson\, Executive Director of CARB-X\, is participating in a special panel discussion titled “When antibiotics fail: An international conversation about the worrisome evidence of impact and what can be done”. During this session\, a panel of international experts will discuss the findings from a new report by the Council of Canadian Academies and discuss what steps can be taken to reduce the impact of rising resistance rates around the world.  Additional panelists include Prof. Andrew Morris\, Prof. Dame Sally Davies\, and Prof. Kathryn Holt. \nAbout the Symposium: \nEach year\, the Gairdner Foundation invites Universities\, Organizations and Research Institutes across Ontario to submit proposals to host a partnered international symposium on the frontiers of biomedicine. \nThis year\, the Michael G. DeGroote Institute for Infectious Disease Research and David Braley Centre for Antibiotic Discovery at McMaster University were honored to have been selected to host the 2019 Gairdner event on the growing global crisis of antimicrobial resistance (AMR). \nDrawing on the Canada Gairdner Awards’ history of recognizing the best in biomedical science\, this symposia will bring leading experts from across the world to present on the state of the international AMR challenge and to showcase recent global advances in AMR research and discovery. \nTo learn more\, click here.  \nTo register\, click here. 
URL:https://carb-x.org/event/the-2019-canada-gairdner-foundation-ontario-international-symposium-fuelling-the-fight-against-amr-global-innovations-in-research-discovery/
LOCATION:McMaster University\, 1280 Main Street W\, Hamilton\, Ontario\, L8S 4L8\, Canada
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20191112T160000
DTEND;TZID=America/Toronto:20191112T190000
DTSTAMP:20260403T232903
CREATED:20191010T184905Z
LAST-MODIFIED:20191010T184905Z
UID:3519-1573574400-1573585200@carb-x.org
SUMMARY:CRISPR and Gene Editing: The New Frontier in Fighting Infectious Diseases?
DESCRIPTION:Presenters include Karen Gallant\, Deputy Executive Director of CARB-X. \nFew technologies have the potential to disrupt and eliminate infectious disease and viral infections– but gene editing\, CRISPR in particular\, is a latent technology that could change biotech – and we’re just seeing the beginning of what effect it could have on the world. \nWith scientific promise comes interest from investors – a surge of biotech startups are utilizing CRISPR technology for many different applications such as at-home testing\, in-clinic uses\, and more. “This incredibly powerful repurposing of the bacterial immune system has created an outpouring of financial backing for small companies with revolutionary technological advancement in genome engineering-based ventures.”[1] \nOn November 12th\, we will explore this subject with presentations from experts in the field\, startup companies innovating in this space\, and investors looking to invest in these new applications. \nTo learn more\, click here. 
URL:https://carb-x.org/event/crispr-and-gene-editing-the-new-frontier-in-fighting-infectious-diseases/
LOCATION:JLabs @ Toronto\, 661 University Ave Suite 1300\, Toronto\, Ontario\, Canada
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191107T110000
DTEND;TZID=America/New_York:20191107T123000
DTSTAMP:20260403T232903
CREATED:20190913T040059Z
LAST-MODIFIED:20190913T154657Z
UID:3423-1573124400-1573129800@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Converting Gram-positive-only compounds into broad-spectrum antibiotics
DESCRIPTION:This webinar by Paul Hergenrother (Department of Chemistry and the Institute for Genomic Biology University of Illinois\, US) will detail his research group’s efforts to understand compound accumulation in the Gram-negative ESKAPE pathogens. Emphasis will be placed on the practicality\, actionability\, and translatability of this information\, specifically\, the use of accumulation rules to convert high-value Gram-positive-only compounds into antibiotics with activity against key Gram-negative pathogens. \nThe presentation will be followed by a Q&A session. \nSpeaker:\nPaul Hergenrother\, Kenneth L. Rinehart Endowed Chair in Natural Products Chemistry\, University of Illinois \nModerator:\nLaura Piddock\, Director of Scientific Affairs\, GARDP \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-converting-gram-positive-only-compounds-into-broad-spectrum-antibiotics/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191107
DTEND;VALUE=DATE:20191109
DTSTAMP:20260403T232903
CREATED:20190923T194433Z
LAST-MODIFIED:20190923T194433Z
UID:3461-1573084800-1573257599@carb-x.org
SUMMARY:World Anti-Microbial Resistance Congress 2019
DESCRIPTION:Kevin Outterson\, Executive Director of CARB-X\, will be giving the keynote Address on November 7th\, titled “A vision for a health antibiotic R&D ecosystem”.  Outterson will also be participating on a panel titled “Analyzing the potential impact of current commercial and “pull” initiatives” on November 7th. \nKaren Gallant\, Deputy Executive Director of CARB-X\, will be presenting on November 7th on “Accelerating innovation to fight drug-resistant bacteria”. \nAbout the World AMR Congress:\nSince 2015\, the World Anti-Microbial Resistance Congress has been the only commercially focused conference globally of its kind.  Launched during the release of key reports such as the AMR Review and A Scientific Roadmap for Antibiotic Discovery\, the World AMR Congress has brought attention to the threats of this emerging crisis to the global healthcare system. The conference gathers global leaders in infectious diseases to meet\, brainstorm and discuss the challenges and opportunities on seven topic areas: \n\nAntibiotic R&D: advancing the development of antibiotic and non-traditional therapies and improving commercialization strategies\nDiagnostics: innovating the development and deployment of rapid diagnostics tests\, while ensuring an effective integration into hospitals’ workflow and reimbursement\nAntimicrobial stewardship: using technology to improve antibiotic prescription\, monitoring and surveillance while advancing stewardship-based purchasing guidelines\nPitch & Partner: joining funding and partnerships with antibiotics and diagnostics innovation\nInfection Control: advancing policies to improve infection prevention\, control and compliance in healthcare facilities\nManufacturing: overcoming challenges for a sustainable and controlled antibiotic manufacturing and supply chain\nVaccines: discussing the clinical and economic value of vaccines to combat AMR\n\nTo learn more\, click here. \nTO view the agenda\, click here. \nTo register\, click here.
URL:https://carb-x.org/event/world-anti-microbial-resistance-congress-2019/
LOCATION:Renaissance Washington DC Downtown Hotel\, 999 9th St NW\, Washington\, DC\, 20001\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191104T160000
DTEND;TZID=America/New_York:20191104T180000
DTSTAMP:20260403T232903
CREATED:20191022T143433Z
LAST-MODIFIED:20191022T143453Z
UID:3542-1572883200-1572890400@carb-x.org
SUMMARY:Challenges in Antimicrobial Resistance - A Conversation with Kevin Outterson
DESCRIPTION:Kevin Outterson\, Executive Director of CARB-X\, will be speaking at the Harvard Chan School of Public Health. \nThis presentation is sponsored by Harvard Antimicrobial Resistance (HAMR) a subgroup of the Harvard Infectious Diseases Consortium. \n\n\n\n\nFor more information\, visit harvardamr.com   \n\n\n\n\n 
URL:https://carb-x.org/event/challenges-in-antimicrobial-resistance-a-conversation-with-kevin-outterson/
LOCATION:Harvard Chan School of Public Health\, 677 Huntington Ave FXB 301\, Boston\, MA\, 02115\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191019
DTEND;VALUE=DATE:20191028
DTSTAMP:20260403T232903
CREATED:20190201T201331Z
LAST-MODIFIED:20191018T153826Z
UID:2292-1571443200-1572220799@carb-x.org
SUMMARY:Institut Pasteur - International Course on Antibiotics and Resistance (ICARE)
DESCRIPTION:Speakers include Erin Duffy\, CARB-X Chief of Research and Development. \nThe emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is currently no course providing advanced instruction on antibiotics and resistance. The specific goal of ICARe is to bring leaders in academics and industry together with trained scientists at the dawn of their careers. Cutting-edge approaches for detection of resistance and antibiotic discovery\, chemical optimization\, and usage that minimizes the development of resistance will be examined. \nThe objective of the course is to train the next generation of scientists implicated in the study of bacterial resistance to antibiotics and the finding of new drugs. The faculty is composed of 40 internationally recognized scientists and physicians who have made important contributions to antibiotic development\, and infectious diseases and resistance management. Faculty will be in residence for a minimum of two days and accessible for informal interactions. Graduates will emerge with a state-of-the-art understanding of existing antibiotics: modes of action\, pharmacology\, toxicology\, mechanisms of resistance\, impact of antibiotics on human and other ecologies\, current approaches for mining chemical space for antimicrobial activity\, the process of advancing hits to leads\, the application of next generation nucleic acid-based technologies for antibiotic discovery and resistance detection\, and perhaps\, most importantly\, training and experience in thinking creatively and innovatively about solutions to the problem. The course aims to build an international cadre of collaborative\, well networked\, and highly trained specialists. \nTo learn more\, click here. \nTo register for the course\, please click here. \nPlease note that registration is currently open and will close on May 17th.
URL:https://carb-x.org/event/institut-pasteur-international-course-on-antibiotics-and-resistance-icare/
LOCATION:Les Pensieres\, Annecy\, France
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191011T120000
DTEND;TZID=America/New_York:20191011T130000
DTSTAMP:20260403T232903
CREATED:20190923T195010Z
LAST-MODIFIED:20190926T124915Z
UID:3463-1570795200-1570798800@carb-x.org
SUMMARY:Live Webcast: Drug-Resistant Infections: Confronting an Escalating Crisis
DESCRIPTION:Antibiotics are a pillar of modern medicine. They have saved millions of lives and added some 20 years to human life expectancy. But as the use of antibiotics has increased\, so has the proliferation of antibiotic-resistant microbes that have adapted to survive most\, or all\, of today’s antibiotics. The CDC reports that two million people are infected with drug-resistant bacteria every year in the United States\, and the Review on Antimicrobial Resistance estimated that\, around the world\, 700\,000 people die of such infections annually. That number stands to increase: the Review predicts that\, by 2050\, drug resistance could be responsible for 10 million deaths a year. And while these numbers are dominated by bacterial infections\, fungal infections like Candida auris are also a threat\, especially to vulnerable patients in hospitals and nursing homes. \nDespite drug resistance growing\, the development of new antibiotics has slowed. How can policymakers help accelerate the pace of new drug development. How can all of us—doctors\, hospitals\, and patients\, as well as the agricultural sector—be better stewards of existing drugs? Forum panelists will examine the scope of this looming crisis and look at how changes in policy and practice can help us stay one step ahead of these superbugs. \nModerator\nDavid Freeman\, Editorial Director of NBC News MACH \nPanelists\nHelen Boucher\, Director\, Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR) and Professor of Medicine at Tufts University School of Medicine \nLauri Hicks\, Director\, Office of Antibiotic Stewardship\, Centers for Disease Control and Prevention \nMarc Lipsitch\, Professor of Epidemiology and Director of the Center for Communicable Disease Dynamics at the Harvard T.H. Chan School of Public Health \nKevin Outterson\, Executive Director of CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator)\, and Professor of Law\, Boston University \nPart of: The Dr. Lawrence H. and Roberta Cohn Forums.\nPresented jointly with NBC News Digital \nLive webcast will be on Friday\, October 11\, 2019\, 12:00pm – 1:00pm ET.\nAn on-demand video will be posted after the event. \nTo learn more\, click here.
URL:https://carb-x.org/event/live-webcast-drug-resistant-infections-confronting-an-escalating-crisis/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191003T110000
DTEND;TZID=America/New_York:20191003T123000
DTSTAMP:20260403T232903
CREATED:20190729T133232Z
LAST-MODIFIED:20190729T133501Z
UID:3229-1570100400-1570105800@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Natural products antibiotics: from traditional screening to novel discovery approaches
DESCRIPTION:In this webinar\, Olga Genilloud will discuss the role of natural products in current antibiotic discovery. Topics discussed will include: \n\nScreening strategies to identify novel antibiotics\nCurrent challenges and novel analytical tools\nNew omic approaches supporting antibiotic discovery\n\nThe presentation will be followed by a Q&A session. \n  \nSpeaker: \nOlga Genilloud\, Scientific Director\, Fundación MEDINA\, Granada\, Spain \nModerator: \nLaura Piddock\, Director of Scientific Affairs\, GARDP \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-natural-products-antibiotics-from-traditional-screening-to-novel-discovery-approaches/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191002
DTEND;VALUE=DATE:20191007
DTSTAMP:20260403T232903
CREATED:20190201T201142Z
LAST-MODIFIED:20190528T161659Z
UID:2290-1569974400-1570406399@carb-x.org
SUMMARY:IDWeek 2019 Annual Conference
DESCRIPTION:Attendees include Richard Alm\, CARB-X Alliance Director. \nIDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA)\, Society for Healthcare Epidemiology of America (SHEA)\, the HIV Medical Association (HIVMA)\, and the Pediatric Infectious Diseases Society (PIDS). \nAt IDWeek\, you will see familiar colleagues and new faces. IDWeek is a forum for health professionals of varied backgrounds to collaborate\, cooperate\, and learn from each other’s expertise. With so many common issues and challenges cutting across our four disciplines\, IDWeek provides an opportunity to learn from each other’s knowledge\, experience and expertise\, for the improvement of patient care and public health. \nThis is an inclusive meeting that offers access to internationally recognized leaders in the field and the opportunity to network with the most highly respected health professionals in infectious diseases\, including HIV. \nTo learn more\, click here. \nTo view the program\, click here. \nTo register for the conference\, click here.
URL:https://carb-x.org/event/idsas-annual-idweek-meeting/
LOCATION:Walter E. Washington Convention Center\, 801 Mount Vernon Pl. NW\,\, Washington D.C.\, DC\, 20001\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190923T180000
DTEND;TZID=America/New_York:20190923T210000
DTSTAMP:20260403T232903
CREATED:20190813T163022Z
LAST-MODIFIED:20190813T163022Z
UID:3280-1569261600-1569272400@carb-x.org
SUMMARY:AMR Challenge: A Night Celebrating Global AMR Fighters
DESCRIPTION:Join HHS Secretary\, Alex Azar\, experts from the U.S. Centers for Disease Control and Prevention\, and hundreds of organizational and global leaders for an evening celebrating the culmination of the AMR Challenge at an unofficial side event of the 74th United Nations General Assembly in New York City.
URL:https://carb-x.org/event/amr-challenge-a-night-celebrating-global-amr-fighters/
LOCATION:Cipriani Midtown\, 110 E. 42nd Street\, New York City\, NY\, 10017\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190910T110000
DTEND;TZID=America/New_York:20190910T123000
DTSTAMP:20260403T232903
CREATED:20190729T132915Z
LAST-MODIFIED:20190729T133433Z
UID:3226-1568113200-1568118600@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Models for antimicrobial R&D: Advanced and complex in vivo models for infectious disease research
DESCRIPTION:In this webinar\, Peter Warn will review the experimental design and conduct of advanced or complex animal models for antimicrobial research. \nThis webinar is designed as a follow on from the webinar of William J. Weiss: Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research (see here: http://bit.ly/2ZiPt6y). \nTopics covered in this webinar will include: \n\nIn depth review of animal models of pneumonia\, UTI and tissue infections including biofilm models.\nAnimal models of non-traditional drugs where CFU might not be a suitable biomarker.\nTips\, hints and pitfalls when trying to generate informative data in PKPD studies.\n\nThe presentation will be followed by a Q&A session. \n  \nSpeaker: \nPeter Warn\, Senior Vice President\, Anti-infective Discovery\, Evotec \nModerator: \nWilliam J. Weiss\, Director\, PreClinical Services\, University of North Texas System College of Pharmacy \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-models-for-antimicrobial-rd-advanced-and-complex-in-vivo-models-for-infectious-disease-research/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190910
DTEND;VALUE=DATE:20190911
DTSTAMP:20260403T232903
CREATED:20190201T204201Z
LAST-MODIFIED:20190201T204201Z
UID:2297-1568073600-1568159999@carb-x.org
SUMMARY:Institut Pasteur Financing Start-Up Breakfast
DESCRIPTION:Additional Details Forthcoming.
URL:https://carb-x.org/event/institut-pasteur-financing-start-up-breakfast/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190906T120000
DTEND;TZID=America/New_York:20190906T180000
DTSTAMP:20260403T232903
CREATED:20190308T181941Z
LAST-MODIFIED:20190722T171323Z
UID:2494-1567771200-1567792800@carb-x.org
SUMMARY:CARB-X Product Developer Conference
DESCRIPTION:We are excited to announce that CARB-X will be hosting our first ever CARB-X Developer Conference. The conference will be held on September 6th\, 2019 in Boston\, immediately following the conclusion of the ASM-ESCMID conference.  Additional details will follow.  Please save the date!\n\n\nThis  will be an excellent networking event for CARB-X product developers\, who will have the opportunity to connect with and learn from some of the most innovative members of the AMR community\, including companies in our diverse portfolio as well as representatives from our expanded accelerator network. \nIf applicable\, please feel free to use your CARB-X travel budget to fund attendance for up to three members of your team.  Allowable incurred travel costs will be reimbursed after the meeting via the standard CARB-X invoicing process.  Please click here for further travel guidance\, and if you have any additional questions please reach out to your CARB-X Finance and Grants Manager for clarity. \nWe will follow up soon with additional details for the CARB-X Product Developer Conference.  Please forward this save-the-date to those interested on your team\, including principle investigators\, science leads\, and project managers.  Please contact Dhanuraj Shetty at dshetty@bu.edu with any urgent questions or concerns. \nMark your calendars and join us on September 6th\, 2019!
URL:https://carb-x.org/event/carb-x-product-developer-conference/
LOCATION:Boston\, Venue Forthcoming
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20190906T081500
DTEND;TZID=Europe/London:20190906T180000
DTSTAMP:20260403T232903
CREATED:20190605T140043Z
LAST-MODIFIED:20190605T140139Z
UID:3092-1567757700-1567792800@carb-x.org
SUMMARY:CeBIL Annual Symposium 2019: Legal Innovation to Support the Development of Antimicrobial Drugs
DESCRIPTION:This symposium explores the complex interactions between law and antimicrobial research and development. Advancing our understanding of this ecosystem will help design a better legal toolkit to promote antimicrobial innovation and limit the impact of resistance on global health. \nHeld at the University of Cambridge\, an international hub for legal and scientific expertise\, we hope the event will mobilize legal\, economic\, business\, medical and scientific experts – early\, mid\, and late career – who recognize the need to work together to avert the AMR crisis. \nClick here to learn more. \nClick here to register.
URL:https://carb-x.org/event/cebil-annual-symposium-2019-legal-innovation-to-support-the-development-of-antimicrobial-drugs/
LOCATION:Christ’s College Cambridge\, St. Andrew's Street\, Cambridge\, CB2 3BU\, United Kingdom
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190906
DTEND;VALUE=DATE:20190909
DTSTAMP:20260403T232903
CREATED:20190201T200954Z
LAST-MODIFIED:20190201T200959Z
UID:2286-1567728000-1567987199@carb-x.org
SUMMARY:5th ESCMID Conference on Vaccines
DESCRIPTION:Online registration will open in spring 2019 – Check back soon for details.
URL:https://carb-x.org/event/5th-escmid-conference-on-vaccines/
LOCATION:Bilbao – Spain\, Bilbao\, Spain
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190904T183000
DTEND;TZID=America/New_York:20190904T210000
DTSTAMP:20260403T232903
CREATED:20190815T140954Z
LAST-MODIFIED:20190815T140954Z
UID:3301-1567621800-1567630800@carb-x.org
SUMMARY:Harvard Museum of Natural History Reception and Mixer
DESCRIPTION:Sponsored by the Harvard Microbial Sciences Initiative and the Boston Area Antimicrobial Research Network \n\n\n\n\nDrinks\, hors d’oeuvres\, and exclusive private access to the Harvard Museum of Natural History https://hmnh.harvard.edu/. This is a chance to unwind with fellow attendees at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance\, and meet those from the Harvard University Microbial Sciences Initiative and Boston Area Antimicrobial Resistance Network sharing that interest. The museum is the quintessential university natural history museum with many unique and historical collections and displays\, located on the main Cambridge campus of Harvard University. \nSPACE IS LIMITED to the first 150 to RSVP.\nTo reserve your place – reply to: michael_gilmore@meei.harvard.edu. Copy the subject line I WILL ATTEND\, and provide your name\, affiliation and email. You will be provided a map\, directions and an ENTRY TICKET in response.
URL:https://carb-x.org/event/harvard-museum-of-natural-history-reception-and-mixer/
LOCATION:Harvard Campus\, 52 Oxford Street\, Cambridge\, MA\, 02138\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190903
DTEND;VALUE=DATE:20190907
DTSTAMP:20260403T232903
CREATED:20190201T200727Z
LAST-MODIFIED:20190214T192208Z
UID:2283-1567468800-1567814399@carb-x.org
SUMMARY:Annual ASM/ESCMID Conference on Antibiotic Development to Meet the Challenge of AMR
DESCRIPTION:The ASM/ECSMID Conference on Drug Development returns to Boston\, Massachusetts for 2019. Check back soon for program details. \nAntimicrobial drug resistance (AMR) is an urgent global health problem. New antimicrobial drug development is increasingly viewed as a priority by National and International bodies. There are relatively few agents in developmental pipelines and a paucity of identified microbiological targets that can be exploited for drug development. Co-sponsored by the American Society for Microbiology (ASM) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID)\, this multidisciplinary meeting will address the challenges\, opportunities and current requirements for antimicrobial drug development for AMR.
URL:https://carb-x.org/event/annual-asm-escmid-conference-on-antibiotic-development/
LOCATION:Boston\, Venue Forthcoming\, Boston\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190820T110000
DTEND;TZID=America/New_York:20190820T123000
DTSTAMP:20260403T232903
CREATED:20190723T181013Z
LAST-MODIFIED:20190723T181112Z
UID:3210-1566298800-1566304200@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE - Models for antimicrobial R&D: Computational modelling for population PK and PKPD
DESCRIPTION:The overall goal of this series of webinars is to provide\, for the non-clinical developer\, an understanding of the risks of development for various kinds of antibacterial products. \nIn this webinar\, Lena Friberg and Elisabet Nielsen (Department of Pharmaceutical Biosciences\, Uppsala University\, Sweden)\, will discuss: \n\nPopulation PK modelling to characterize drug exposure and variability\nPKPD-modelling to characterize preclinical time-kill data\nPKPD-modelling for translation to patients\nModel-based dose-individualization\n\nThe presentation will be followed by a Q&A session. \n  \nSpeakers: \nLena Friberg and Elisabet Nielsen\, Department of Pharmaceutical Biosciences\, Uppsala University\, Sweden \nModerator: \nUrsula Theuretzbacher\, Center for Anti-Infective Agents\, Vienna\, Austria \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-models-for-antimicrobial-rd-computational-modelling-for-population-pk-and-pkpd/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190812T080000
DTEND;TZID=America/New_York:20190813T170000
DTSTAMP:20260403T232903
CREATED:20190206T172158Z
LAST-MODIFIED:20190206T172158Z
UID:2353-1565596800-1565715600@carb-x.org
SUMMARY:UK Medical Research Council National PhD Training Programme in AMR - Annual Conference
DESCRIPTION:Keynote lecture given by Kevin Outterson\, Executive Director of CARB-X. \nAdditional details forthcoming.
URL:https://carb-x.org/event/uk-medical-research-council-national-phd-training-programme-in-amr-annual-conference/
LOCATION:University of Bristol\, Bristol\, BS8 1TD\, United Kingdom
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190724
DTEND;VALUE=DATE:20190726
DTSTAMP:20260403T232903
CREATED:20190611T144303Z
LAST-MODIFIED:20190611T144303Z
UID:3107-1563926400-1564099199@carb-x.org
SUMMARY:The Role of NIH in Drug Development Innovation and its Impact on Patient Access: A workshop
DESCRIPTION:This is an open session hosted by the National Academy of Sciences\, Engineering\, and Medicine.  The 1.5-day public workshop to will be held on July 24-25\, 2019 in Washington\, D.C and focus on the translation of federal investments in biomedical science to innovation in drug development and how the public benefits from that investment in terms of drug pricing and access. The meeting will feature invited presentations and panel discussions on topics that may include: \n  \n\nhow federal funding for biomedical research\, particularly via NIH\, has contributed to new drug development\, both directly and indirectly\nthe pricing of drugs that have benefited from federal investments in biomedical science;\nthe role of technology and patent transfer to and from entrepreneurial organizations associated with NIH-funded research\npotential ways to better track\, quantify\, and document NIH contributions to innovation in drug development\npotential strategies and policies to facilitate the translation of federally-funded biomedical research into innovations in drug development and to help ensure that the public has affordable access to those innovative medicines.\nThe planning committee will develop the agenda\, select and invite subject matter experts and discussants\, and moderate the discussions. A proceedings of the event will be prepared in accordance with institutional guidelines.\n\nTo learn more\, click here.
URL:https://carb-x.org/event/the-role-of-nih-in-drug-development-innovation-and-its-impact-on-patient-access-a-workshop/
LOCATION:The National Academies Keck Building\, 500 5th Street NW\, Washington\, DC\, 20001\, United States
END:VEVENT
END:VCALENDAR